Cocrystal Pharma Faces CRO Dispute Amidst Mixed Clinical Trial Results

TL;DR

**COCP's influenza program is a mess with a $6.3M CRO dispute, but their norovirus drug CDI-988 shows promise, making it a speculative buy on future trial success.**

AI Summary

Cocrystal Pharma, Inc. (COCP) is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics for serious viral diseases. For the fiscal year ended December 31, 2025, the company continued its research and development efforts in influenza, norovirus, and coronavirus programs. The oral CC-42344 Phase 2a human challenge study for influenza A faced a significant setback due to unexpectedly low influenza infection rates, leading to a dispute with the CRO over a $6,309,000 payment and an additional $600,000 claim from the CRO. Despite this, CC-42344 showed potential efficacy against the new Texas avian flu strain in June 2024 in vitro studies. The company's CDI-988, a novel protease inhibitor for noroviruses and coronaviruses, demonstrated favorable safety and tolerability in Phase 1 SAD and MAD cohorts, including a 1200 mg high-dose cohort, with results presented in August 2025. In December 2025, Cocrystal received IRB approval and commenced subject screening for a Phase 1b norovirus challenge study at Emory University School of Medicine, which began in February 2026. The aggregate market value of common equity held by non-affiliates was approximately $11.6 million as of June 30, 2025.

Why It Matters

Cocrystal Pharma's progress in antiviral development, particularly with CC-42344 and CDI-988, holds significant implications for public health and investors. The dispute with the CRO over the failed CC-42344 Phase 2a study, involving $6.3 million, highlights operational risks and could impact future funding and development timelines, potentially delaying a much-needed influenza treatment. Success with CDI-988 in norovirus and coronavirus could position Cocrystal as a key player in a competitive antiviral market, offering a broad-spectrum solution against emerging variants like KP.3.1.1 and LP.8.1, which are currently under WHO monitoring. This could attract partnerships and provide a competitive edge against larger pharmaceutical companies.

Risk Assessment

Risk Level: high — The company faces high risk due to the significant dispute with its CRO regarding the failed Phase 2a influenza study, involving a requested refund of $6,309,000 and an additional claim of approximately $600,000 from the CRO. This financial and operational setback directly impacts the development of CC-42344. Furthermore, the aggregate market value of voting and non-voting common equity held by non-affiliates was only approximately $11.6 million as of June 30, 2025, indicating a small market capitalization and potentially limited financial flexibility.

Analyst Insight

Investors should closely monitor the arbitration outcome of the CRO dispute, as it will significantly impact Cocrystal's financial health and the future of its influenza program. Given the promising Phase 1 data for CDI-988, consider this a high-risk, high-reward speculative play, contingent on successful Phase 1b norovirus challenge study results and subsequent clinical progression.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $6.3M — CRO payment dispute (refund requested for failed CC-42344 Phase 2a study)
• $11.6M — Market Value (Non-Affiliate Equity) (as of June 30, 2025, indicating small market capitalization)
• 13,785,759 — Shares Outstanding (as of March 24, 2026)
• 1200 mg — CDI-988 High Dose (evaluated in Phase 1 study with favorable safety)
• 777 million — COVID-19 Reported Cases (globally as of February 2026)
• 7 million — COVID-19 Deaths (globally as of February 2026)
• 1 billion — Seasonal Influenza Cases (worldwide annually, according to WHO)
• 650,000 — Seasonal Influenza Deaths (worldwide annually, according to WHO)
• 8% — US Population Influenza Rate (contracts influenza each season, according to CDC)
• $10.4 billion — US Annual Influenza Medical Costs (according to NIH)

Key Players & Entities

• Cocrystal Pharma, Inc. (company) — clinical-stage biotechnology company
• CC-42344 (company) — novel PB2 inhibitor for influenza A
• CDI-988 (company) — novel protease inhibitor for noroviruses and coronaviruses
• United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) (regulator) — authorized Phase 2a study for CC-42344
• Emory University School of Medicine (company) — clinical study site for Phase 1b norovirus trial
• Dr. Roger Kornberg (person) — Chief Scientist and Chairman of Scientific Advisory Board and Board of Directors
• $6,309,000 (dollar_amount) — refund requested from CRO for failed Phase 2a study
• $600,000 (dollar_amount) — additional amount CRO is seeking from the Company
• $11.6 million (dollar_amount) — aggregate market value of common equity held by non-affiliates as of June 30, 2025
• FDA (regulator) — issued Study May Proceed Letter for Phase 1b challenge study

FAQ

Risk Factors

• Clinical Trial Setback and CRO Dispute [high — operational]: The Phase 2a human challenge study for CC-42344 faced a significant setback due to unexpectedly low influenza infection rates. This led to a dispute with the CRO over a $6,309,000 payment, with the company requesting a refund. An additional $600,000 claim from the CRO exacerbates this operational challenge.
• Limited Market Capitalization [medium — financial]: The aggregate market value of common equity held by non-affiliates was approximately $11.6 million as of June 30, 2025. This indicates a small market capitalization, which can impact the company's ability to raise capital and its overall financial flexibility.
• Drug Development and Approval Pathway [high — regulatory]: As a clinical-stage biotechnology company, Cocrystal Pharma is subject to the rigorous and lengthy drug development and approval processes by regulatory bodies like the FDA. Delays or failures in clinical trials, such as the CC-42344 study, can significantly impact the company's timeline and financial resources.

Industry Context

Cocrystal Pharma operates in the highly competitive biotechnology sector, focusing on antiviral therapeutics. The company faces significant challenges from established pharmaceutical companies and other emerging biotechs developing treatments for widespread viral diseases like influenza and COVID-19. The industry is characterized by long development cycles, high R&D costs, and stringent regulatory hurdles, with a constant need for innovation to address evolving viral strains and unmet medical needs.

Regulatory Implications

As a clinical-stage company, Cocrystal Pharma is heavily reliant on successful navigation of the FDA's drug approval process. Setbacks in clinical trials, such as the CC-42344 influenza study, can lead to significant delays and increased costs, potentially jeopardizing the drug's path to market. Compliance with Good Clinical Practice (GCP) and other regulatory standards is paramount for all ongoing and future studies.

What Investors Should Do

1. Monitor resolution of the CRO payment dispute.
2. Track progress of the CDI-988 Phase 1b norovirus challenge study.
3. Assess the potential of CC-42344 against emerging avian flu strains.
4. Evaluate the company's cash runway and future financing needs.

Key Dates

• 2024-06-01: In vitro studies showed CC-42344 potential efficacy against new Texas avian flu strain — Provides a glimmer of hope for the CC-42344 program despite the Phase 2a setback, suggesting potential utility against emerging strains.
• 2025-08-01: Phase 1 SAD and MAD cohort results for CDI-988 presented — Demonstrated favorable safety and tolerability for CDI-988, including a 1200 mg high-dose cohort, supporting progression to further clinical studies.
• 2025-06-30: Aggregate market value of common equity held by non-affiliates was approximately $11.6 million — Indicates a small market capitalization, which can affect fundraising capabilities and investor perception.
• 2025-12-01: Received IRB approval and commenced subject screening for Phase 1b norovirus challenge study — Marks a significant step forward for the CDI-988 program, initiating a human challenge study for norovirus indication.
• 2026-02-01: Phase 1b norovirus challenge study began at Emory University School of Medicine — The commencement of the human challenge study is critical for evaluating CDI-988's efficacy against norovirus in a controlled setting.
• 2026-03-24: 13,785,759 Shares Outstanding — Provides an updated share count, important for per-share calculations and understanding ownership structure.

Glossary

CRO

Contract Research Organization. A company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services. (Cocrystal Pharma is involved in a payment dispute with its CRO regarding a failed clinical trial, highlighting the financial and operational risks associated with outsourcing research.)

Phase 2a human challenge study

A type of clinical trial where healthy volunteers are intentionally exposed to a pathogen (in this case, influenza) under controlled conditions after receiving a potential treatment, to assess its efficacy and safety. (The failure of such a study for CC-42344 due to low infection rates directly impacted the company's development timeline and led to financial disputes.)

in vitro studies

Studies conducted in a controlled environment outside of a living organism, such as in a test tube or petri dish. (Positive in vitro results for CC-42344 against a new avian flu strain offer some indication of potential efficacy, even after a clinical trial setback.)

SAD and MAD cohorts

Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) are phases in early-stage clinical trials (Phase 1) designed to evaluate the safety, tolerability, and pharmacokinetic profile of a drug by administering increasing doses to small groups of healthy volunteers. (Favorable safety and tolerability results in these cohorts for CDI-988 are crucial for advancing the drug into later-stage trials.)

protease inhibitor

A type of medication that inhibits the activity of proteases, which are enzymes essential for viral replication. (CDI-988 is a protease inhibitor being developed for noroviruses and coronaviruses, targeting a key mechanism for viral survival.)

IRB approval

Institutional Review Board approval. A committee that reviews and approves research protocols involving human subjects to ensure ethical conduct and protection of participants' rights and welfare. (IRB approval is a mandatory step before commencing human clinical trials, and its receipt for the norovirus study signifies progress for CDI-988.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available in the provided text excerpt. The filing focuses on the current fiscal year's operations and forward-looking statements.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share COCP The Nasdaq Stock Mar
• $6,309,000 — d is requesting that the CRO refund the $6,309,000 it was paid or redo the study. The CRO
• $600,000 — to recover an additional approximately $600,000 from the Company. As of the date of thi
• $10.4 billion — luenza is responsible for approximately $10.4 billion in direct medical costs in the U.S. ann
• $10.6 billion — e annual burden to the United States at $10.6 billion. Noroviruses are responsible for up to

Filing Documents

• form10-k.htm (10-K) — 1408KB
• ex23-1.htm (EX-23.1) — 5KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 11KB
• ex31-3.htm (EX-31.3) — 12KB
• ex32-1.htm (EX-32.1) — 13KB
• chart_01.jpg (GRAPHIC) — 92KB
• 0001493152-26-013838.txt ( ) — 6081KB
• cocp-20251231.xsd (EX-101.SCH) — 45KB
• cocp-20251231_cal.xml (EX-101.CAL) — 57KB
• cocp-20251231_def.xml (EX-101.DEF) — 157KB
• cocp-20251231_lab.xml (EX-101.LAB) — 428KB
• cocp-20251231_pre.xml (EX-101.PRE) — 330KB
• form10-k_htm.xml (XML) — 632KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 39 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 42 Item 8.

Financial Statements

Financial Statements. 42 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. 43 Item 9A.

Controls and Procedures

Controls and Procedures. 43 Item 9B. Other Information. 43 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 43 Part III. 44 Item 10. Directors, Executive Officers and Corporate Governance. 44 Item 11.

Executive Compensation

Executive Compensation. 49 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 52 Item 13. Certain Relationships and Related Transactions, and Director Independence. 53 Item 14. Principal Accounting Fees and Services. 54 Part IV. 55 Item 15. Exhibits, Financial Statement Schedules. 55 Item 16. Form 10-K Summary 56

SIGNATURES

SIGNATURES 57 2 PART I Item 1. Business. Overview Cocrystal Pharma, Inc. (the "Company" or "Cocrystal") is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise with the goal of creating viable antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising discovery, preclinical and clinical stage antiviral compounds for unmet medical needs caused by RNA viruses including influenza virus, norovirus, coronaviruses (including SARS-CoV-2 & MERS-CoV), respiratory virus infections and hepatitis C virus ("HCV") infections. The Company operates as one business entity. Cocrystal Technology We are developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. Our goals include treating and preventing influenza virus, norovirus, and coronavirus infections by discovering and developing direct-acting antiviral drug candidates targeting required steps in the viral replication process. To discover and design these direct-acting antiviral drug candidates, we use a proprietary platform comprising computational chemistry, medicinal chemistry, X-ray crystallography and our extensive know-how. We determine the structures of cocrystals containing the inhibitors bound to the viral enzyme or protein to guide our structure-based drug design. We also use advanced computational methods to screen and design product candidates using proprietary high-resolution cocrystal structural information. In designing the candidates, we seek to anticipate and avert potential viral mutations leading to resistance. By designing and selecting drug candidates that interrupt the viral replication proce

View Full Filing

View this 10-K filing on SEC EDGAR